Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Targeted Anticancer Therapies Congress 2024

Mutant specific inhibitors

Novel mutant-selective EGFR/HER2 kinase inhibitors: Insights and perspectives

Date

27 Feb 2024

Session

Mutant specific inhibitors

Topics

Clinical Research;  Translational Research;  Cancer in Older Adults;  Immunotherapy

Tumour Site

Presenters

Capucine Baldini

Authors

C. Baldini

Author affiliations

  • Drug Development Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Q&A and discussion

Presenter: All Speakers

Session: Mutant specific inhibitors

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.